IPR v. Ex Parte Reexam Strategy Considerations
February 7, 2024, 7:16 AM
Looking forward to presenting at the AIPLA IP Practice in Japan Mid-Winter Program in Houston, TX next week!
I will be discussing the strategic considerations for Inter Partes Review (IPR) versus Ex Parte Reexamination, including:
- The procedural differences between IPR and Ex Parte Reexamination and associated statistics
- The circumstances when one may be preferable over the other
- The effects of timing and estoppel in parallel litigations
My colleague, Jason Murata, another partner in Axinn’s Intellectual Property group, will be covering, “Recent Developments in the Generic Pharma Industry in the U.S.”

To subscribe to our publications, click here.
News & Insights
News & Insights
NBA CLS 39th Annual Corporate Counsel Conference
Sponsorship
Antitrust
New Frontiers of Antitrust – 16th Annual International Conference of Concurrences Review
Speaking Engagement
Antitrust
GCR Live Global: Navigating the Future of Antitrust 2026
Speaking Engagement
Antitrust
Stakeholders 25th Annual CYOC Career Development Conference
Sponsorship
Antitrust
American Investment Council’s General Counsel Day
Speaking Engagement
Antitrust
Informa 34th Annual Advanced EU Brussels Conference
Speaking Engagement
Antitrust
Kisaco Research Pharma and Biotech Patent Litigation Summit 2025
Speaking Engagement
Intellectual Property
GCR Live: Women in Antitrust 2025
Speaking Engagement
Antitrust
Global Legal Group Global Class Actions Symposium 2025
Speaking Engagement
Litigation & Trials
Biosimilar Approval Pathway Changes Sponsors Need to Monitor
Media Mentions
Intellectual Property